Peel Hunt reissued their buy rating on shares of PureTech Health (LON:PRTC) in a research report released on Wednesday, ThisIsMoney.Co.Uk reports.
Several other research analysts have also commented on the company. Liberum Capital reissued a buy rating on shares of PureTech Health in a research report on Monday, April 15th. Jefferies Financial Group reissued a buy rating and issued a GBX 255 ($3.33) price objective on shares of PureTech Health in a research report on Thursday, March 7th.
LON:PRTC opened at GBX 185 ($2.42) on Wednesday. The company has a debt-to-equity ratio of 5.73, a quick ratio of 0.94 and a current ratio of 0.97. PureTech Health has a 12 month low of GBX 135 ($1.76) and a 12 month high of GBX 188.50 ($2.46). The stock has a market capitalization of $522.61 million and a price-to-earnings ratio of 7.17.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.